Trial reportBritish journal of anaesthesia2025
Effect of intraoperative paravertebral or intravenous lidocaine infusion on postoperative complications and inflammation after lung resection surgery: a randomised controlled trial.
Trial report in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03905837 (Impact of the Administration of Intravenous or Paravertebral Lidocaine in Continuous Perfusion During the Intraoperative Period of Lung Resection Surgery on the Appearance of Postoperative Complications), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of the Administration of Intravenous or Paravertebral Lidocaine in Continuous Perfusion During the Intraoperative Period of Lung Resection Surgery on the Appearance of Postoperative Complications
Who cites it
5 citing papers in PubMed.
- Optimizing neoadjuvant chemoimmunotherapy cycles based on radiologic response improves efficacy and survival in non-small cell lung cancer.Translational lung cancer research · 2026Article
- Pain management strategies following thoracic surgery: best practices and innovations.Journal of thoracic disease · 2026Review
- An update on the role of multimodal analgesia in perioperative pain management.Korean journal of anesthesiology · 2026Review
- Lidocaine as a promising adjunct to reduce complications after lung resection.Journal of thoracic disease · 2026Article
- Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential for the anti-inflammatory effects of lidocaine to reduce complications after lung resection has not been evaluated. We assessed whether intraoperative i.v. or paravertebral lidocaine, compared with remifentanil, reduced complications after lung resection. We also quantified pulmonary and systemic inflammatory responses.
methodsThis single-centre study randomised participants undergoing lung resection (video-assisted thoracoscopy) to receive continuous infusion of either (1) i.v. lidocaine and paravertebral saline, (2) paravertebral lidocaine and i.v. saline, or (3) remifentanil and paravertebral saline. The primary outcome was the proportion of participants with all-cause complications (Clavien-Dindo classification). Cytokines were measured in bronchoalveolar lavage fluid before and after one-lung ventilation and in plasma during the first 24 h.
resultsIn 154 patients (mean age 65 yr; 42% female), fewer major (Clavien-Dindo Grade ≥III) complications were recorded in participants randomised to intraoperative paravertebral (two of 49; 4.1%) or i.v. (two of 54; 3.7%) lidocaine, compared with six of 51 (11.8%) participants who received remifentanil (P=0.037). Severe complications were less likely with lidocaine from either i.v. or paravertebral sources, compared with remifentanil (odds ratio: 0.44 [95% confidence interval: 0.22-0.88]). Pulmonary complications occurred in 23/103 (22.3%) participants allocated to intraoperative lidocaine from either i.v. or paravertebral routes, compared with 23/51 (45.1%) participants who received remifentanil (odds ratio: 0.35 [95% confidence interval: 0.17-0.72]; P=0.004). Cytokine levels after one-lung ventilation were lower with lidocaine treatment.
conclusionsIntraoperative lidocaine infusion administered either intravenously or through paravertebral catheter reduces the incidence and severity of complications after lung resection surgery compared with remifentanil. Lidocaine might confer this benefit through reducing systemic and lung inflammation. CLINICAL
trial registrationNCT03905837.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.